U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16ClNO2S.ClH
Molecular Weight 358.283
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPIDOGREL HYDROCHLORIDE

SMILES

Cl.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl

InChI

InChIKey=XIHVAFJSGWDBGA-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H16ClNO2S
Molecular Weight 321.822
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Preventing
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.521 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
15800 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4600 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2520 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1500 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.09 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
0.767 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
50600 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9890 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7440 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
3130 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.9 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.4 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
8.5 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
Health Status: healthy
Age Group: 20-45 years
Sex: M
Sources:
Other AEs: Uric acid abnormal...
Other AEs:
Uric acid abnormal (5 patients)
Sources:
1650 mg single, oral
Overdose
Dose: 1650 mg
Route: oral
Route: single
Dose: 1650 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Disc. AE: Transaminases increased, Fever...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Uric acid abnormal 5 patients
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
Health Status: healthy
Age Group: 20-45 years
Sex: M
Sources:
Fever 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Transaminases increased 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
yes [IC50 0.307 uM]
yes [IC50 6.25 uM]
yes [Ki 28 uM]
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
no
no
no
no
no
no
yes [Km 181 uM]
yes [Km 19 uM]
yes [Km 20.9 uM]
yes [Km 5.61 uM]
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers.
1998
Drug-induced thrombotic microangiopathy: incidence, prevention and management.
2001
Atherothrombosis: a major health burden.
2001
Novel platelet inhibitors.
2001
Antithrombotic drugs for secondary stroke prophylaxis.
2001 Apr
Results of CURE trial for acute coronary syndrome.
2001 Apr 11
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.
2001 Feb 6
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.
2001 Jan
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
2001 Jan 23
Febrile pancytopenia associated with clopidogrel.
2001 Jan 8
Clopidogrel (Plavix): hematological reactions.
2001 Jan 9
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.
2001 Jul
Diffuse alveolar hemorrhage after clopidogrel use.
2001 Jul
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
2001 Jul 31
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
2001 May
Antiplatelet agents for secondary prevention of ischemic stroke.
2001 Oct
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
2001 Sep
Patents

Sample Use Guides

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose of is 75 mg once daily.
Route of Administration: Oral
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:57:39 GMT 2025
Edited
by admin
on Mon Mar 31 18:57:39 GMT 2025
Record UNII
426O7XWS6Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOPIDOGREL HYDROCHLORIDE
EMA EPAR   WHO-DD  
Common Name English
CLOPIDOGREL MYLAN
Preferred Name English
CLOPIDOGREL TEVA GENERICS B.V.
Brand Name English
CLOPIDOGREL HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CLOPIDOGREL-TAD
Brand Name English
CLOPIDOGREL QUALIMED
Brand Name English
CLOPIDOGREL HYDROCHLORIDE [EMA EPAR]
Common Name English
CLOPIDOGREL-DURA
Brand Name English
Clopidogrel hydrochloride [WHO-DD]
Common Name English
CLOPIDOGREL TEVA PHARMA
Brand Name English
CLOPIDOGREL-HCS
Brand Name English
CLOPIDOGREL-KRKA
Brand Name English
THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, HYDROCHLORIDE, (S)-
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-TAD (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TAD (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL DURA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-DURA (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-KRKA (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL DURA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
NCI_THESAURUS C80483
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL TAD (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL HCS (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
Code System Code Type Description
DRUG BANK
DBSALT002594
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
SMS_ID
100000115888
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
CAS
120202-65-5
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
PUBCHEM
9798860
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
FDA UNII
426O7XWS6Y
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
NCI_THESAURUS
C96893
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
EVMPD
SUB30779
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID40152734
Created by admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY